184970-28-3

Basic information

• Product Name: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE
• Synonyms: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE;4-Bromo-2-bromomethylanisole
• CAS NO: 184970-28-3
• Molecular Formula: C₈H₈Br₂O
• Molecular Weight: 279.96
• Mol File: 184970-28-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(184970-28-3)
• EPA Substance Registry System: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(184970-28-3)

Safety Data

• Hazardous Substances Data: 184970-28-3(Hazardous Substances Data)

Usage

Uses

Due to the limited available data on 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE, its specific applications are not clearly outlined in the provided materials. However, given its chemical structure and the presence of bromine and methoxy groups, it can be inferred that this compound may have potential uses in various industries, such as:
Used in Chemical Synthesis Industry:
4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE could be used as an intermediate or a building block in the synthesis of more complex organic compounds, particularly those requiring bromine and methoxy functionalities.
Used in Pharmaceutical Industry:
Given the presence of bromine and methoxy groups, 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE might be utilized in the development of new pharmaceutical compounds, where these functional groups could contribute to the desired biological activity or improve the drug's pharmacokinetic properties.
Used in Material Science:
4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE's aromatic structure and bromine content could make it a candidate for the development of new materials with specific properties, such as flame retardancy or enhanced thermal stability.

Upstream product

• 80866-82-6 5-bromo-2-methoxy-benzyl alcohol 
• 14804-31-0 2-methyl-4-bromoanisole 

Downstream Products

• 88857-57-2 2-<2-(5-Brom-2-methoxy-phenyl)-ethyl>-benzoesaeure 
• 954123-89-8 tert-butyl 4-((5-bromo-2-methoxybenzyloxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 144649-99-0 5-bromo-2-methoxybenzonitrile 
• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 876918-26-2 5-bromo-2-isobutoxy-benzonitrile 
• 1139901-88-4 tert-butyl 2-(3’-cyano-4’-isobutoxyphenyl)-4-methylthiazole-5-carboxylate 
• 144060-53-7 febuxostat 
• 685126-64-1 2-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-phenyl}-4-isopropyl-1-methyl-4,5-dihydro-1H-imidazole 

Relevant articles and documents

Synthesis and Evaluation of Europium Complexes that Switch on Luminescence in Lysosomes of Living Cells

A set of four luminescent EuIII complexes bearing an extended aryl-alkynylpyridine chromophore has been studied, showing very different pH-dependent behaviour in their absorption and emission spectral response. For two complexes with pKa/

PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS

The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.

One-pot transformation of methylarenes into aromatic aldehydes under metal-free conditions

On the basis of studies of the transformation of benzylic bromides into the corresponding aromatic aldehydes by treatment with N-methylmorpholine N-oxide, various methylarenes were treated either with DBDMH in the presence of AIBN in acetonitrile at reflux (Method A) or with NBS in CCl4 under irradiation with a tungsten lamp at 30 °C (Method B), followed by treatment with N-methylmorpholine N-oxide to provide aromatic aldehydes in good yields. These methods could be adopted in one-pot transformations of methylarenes into aromatic aldehydes under conditions free of less toxic reagents and transition metals. Copyright

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

Direct oxidative conversion of methylarenes into aromatic nitriles

A variety of methylarenes were successfully converted into the corresponding aromatic nitriles in good to moderate yields by the treatment with NBS or DBDMH in the presence of a catalytic amount of AIBN or BPO, followed by the reaction with molecular iodine in aq NH3 in a one-pot procedure. The present reaction is a useful and practical transition-metal-free method for the preparation of aromatic nitriles from methylarenes.

A concise synthesis of 4′-O-methyl honokiol

A concise and protecting group free synthesis of the naturally occurring neolignan 4′-O-methyl honokiol is developed. The key biaryl bond is constructed by 1,2-addition of an aryl Grignard reagent to a dienone followed by rearrangement.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES

The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide deriva